About TolerogenixX

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

Press releases

Press
23. May 2017

TolerogenixX secures seed funding and completes Phase I clinical trial

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. In a Phase I clinical trial, the technique was successfully employed during kidney transplants. Patients who received transplants became tolerant of the donated organ. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance thi
 

Info & Contact

Dr. Matthias Schaier
Phone:
+49 6221 5639930
Web:
www.tolerogenixx.com

Address

TolerogenixX GmbH
Im Neuenheimer Feld 162
69120 Heidelberg

In portfolio

21. Dec 2016

Sector

 

Ulrike Kalapis

Investment Manager